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ferences in the appropriate prescribing of tegaserod in patients
whose plan required PA (n = 998) compared with patients whose
plans did not require PA (n = 1640) (94.1% vs 93.4%, respec-
tively, p = 0.45). CONCLUSIONS: Most patients receiving
tegaserod had a diagnostic claim for IBS or one of its cardinal
symptoms (abdominal pain, bloating, or constipation), indicat-
ing that tegaserod is being prescribed appropriately. Moreover,
our analysis revealed that PA for tegaserod did not have an effect
on appropriate GI prescribing, thus bringing into question the
value of PA.
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OBJECTIVES: to examine the utilization trends of gastric acid-
suppressive drugs, including Proton Pump Inhibitors (PPIs) and
Histamine-2 Receptor Inhibitors (H2RAs) between 1995 and
2005. METHODS: Patient records and prescription records
were analyzed for patients enrolled in the General Practice
Research Database in the UK. The prevalence of PPIs and
H2RAs use from 1995 to 2005 were compared. The average
number of prescriptions per person per month was calculated for
users of PPIs and H2RAs, respectively. Age and gender of users
of PPIs and H2RAs were compared between 1995 and 2005.
RESULTS: One-year prevalence of PPIs use increased from 33.5
per 1000 persons in 1995 to 52.2 per 1000 in 2005. Alterna-
tively, one-year prevalence of H2RAs use decreased from 53.0
per 1000 in 1995 to 13.1 per 1000 in 2005. In 1995, the average
monthly number of H2RAs prescriptions was 0.34 (SE = 0.32),
and the monthly number of PPIs prescriptions was 0.35 (SE =
0.33). In 2005, monthly mean number of H2RAs prescriptions
was 0.34 (SE = 0.35), and the monthly number of PPIs pre-
scriptions was 0.42 (SE = 0.40). The number of PPIs prescrip-
tions is signiﬁcantly higher in 2005 than that in 1995 (P < 0.01).
From 1995 to 2005, the mean age of PPIs users decreased from
69.0(SE = 16.9) to 61.8(SE = 17.3) and the mean age of H2RAs
users decreased from 68.7 (SE = 12.7) to 60.0(SE = 19.6) 
(p < 0.01 for both PPIs and H2RAs). The proportion of users
less than 60 years old signiﬁcantly increased from 1995 to 2005
(p < 0.01 for PPIs and H2RAs). CONCLUSION: In the general
practice setting of UK, the annual prevalence of PPI use increased
with reduced prevalence of H2RA use in the past decade. The
monthly number of prescription of PPIs signiﬁcantly increased
from 1995 to 2005. Users of gastric-acid suppressive drugs
trended younger over time. The economic and epidemiologic
impact of this trend needs to be studied further.
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OBJECTIVES: Determine the changes in utilization of physician,
emergency department, and hospital outpatient services related
to constipation and Irritable Bowel Syndrome (IBS) over the past
10 years. METHODS: This study was a retrospective analysis 
of the National Ambulatory Medical Care Survey (NAMCS) 
and the National Hospital Ambulatory Medical Care Survey
(NHAMCS) from 1993–2003. The NAMCS and NHAMCS are
national probability surveys of visits to ofﬁce-based physicians
and ambulatory services in hospital emergency and outpatient
departments. Constipation visits were identiﬁed based on a
reason for visit or a diagnosis of constipation (ICD-9-CM =
564.0). IBS visits were identiﬁed based on a diagnosis of IBS
(ICD-9-CM = 564.1) or a prescription for alosetron or tegaserod.
Sensitivity analyses were performed to explore the impact of
various case deﬁnitions. RESULTS: In 2003, 8.81 million
(95%CI: 6.73 million–10.90 million) visits were related to con-
stipation, 7.04 million physician ofﬁce visits, 1.15 million emer-
gency department visits, and 0.63 million outpatient hospital
department visits—representing over a 400% increase compared
to the 2.20 million total visits made in 1993. In 2003, 67.0% of
visits were made by females, 20.9% by those less than 10 years
old, and 38.5% by those 65 and older, and 11.0% by blacks.
There were over 3.53 million IBS related visits in 2003 which is
16% higher than the 2.97 million visits in 1995. In 2003, 92.0%
of visits were made by females, 30.0% were made by persons
between 25–44 years of age, and 9.0% were made by blacks.
CONCLUSIONS: Over the past ten years, ambulatory visits to
treat constipation have increased dramatically across all regions
of the country, races, and ages, but have particularly increased
for infants and children. Over a similar time period, IBS visits
have remained relatively stable but represent a sizable reason
persons, particularly women, contact the U.S. ambulatory care
setting.
GI DISORDERS—Methods and Concepts
PGI18
A NEW APPROACH TO USING SELF-REPORTED UTILIZATION
TO ESTIMATE COST ASSOCIATED WITH MILD, MODERATE,
AND SEVERE GERD-RELATED SYMPTOMS
Doan QV1,Aguilar D1, Elfant AB2, Lange SM3, Reyes E1, Dean BB1,
Lynn RB4, Dubois RW1
1Cerner Health Insights, Beverly Hills, CA, USA, 2Cooper
Hospital/University Medical Center, Camden, NJ, USA, 3Mayo Clinic
Jacksonville, Jacksonville, FL, USA, 4Wyeth Pharmaceuticals,
Collegeville, PA, USA
OBJECTIVES: Previous literature reported patients with GERD
have $240 more in medical care costs compared with patients
without GERD (JMCM 2003;7:6–13). However, no data exist
to differentiate these costs by symptom severity. This study’s
purpose was to assess utilization and costs associated with mild,
moderate, and severe GERD-related symptoms using a new
approach. METHODS: An Internet-based survey of US adults
was conducted using GERD Symptom & Medication Question-
naire (GERD-SMQ), a validated screening tool. Severity of heart-
burn and acid regurgitation symptoms were rated on a 10-point
scale. The highest rating value of heartburn and acid regurgita-
tion was used. Respondents were classiﬁed into the following
severity strata: mild (1–4), moderate (5–7), and severe (8–10).
Subjects were asked to report the frequency of hospitalizations,
emergency room visits, physician ofﬁce visits, tests, and proce-
dures relating to GERD over the past six months. Utilization 
of each component was converted into monetary value using
publicly available fee schedules. Imputed costs for each severity
stratum were summed and divided by the average total imputed
cost among all cases to determine the utilization weights relative
to the “average” GERD case. Utilization weights were multiplied
by $240 to estimate cost for each severity stratum. RESULTS: A
total of 701 GERD cases were identiﬁed: 22.1%, 48.6%, and
24.0% were categorized as mild, moderate, and severe and the
remaining 5.3% as having no active symptoms. Compared with
“average” GERD cases, patients classiﬁed as having mild, mod-
erate, and severe GERD-related symptoms had relative utiliza-
tion weights of 0.404, 0.610, and 2.458 respectively, and
GERD-attributable costs of $97, $146, and $590 per year
